Generic Medicine Info
Should be taken with food. Take w/ or immediately after meals.
History of peptic ulceration, porphyria, inflammatory bowel disease, blood disorders, hypersensitivity. Not to be used in acute gout of elderly with even mild renal function. Lactation. Severe renal disease.
Special Precautions
Allergic disorders, coagulation defects; renal, cardiac or hepatic impairment; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, pregnancy. Should be withdrawn if GI lesions develop. Long-term use of NSAID is associated with reversible, reduced female fertility. Maintain adequate fluid intake.
Adverse Reactions
GI disorders; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity, haematuria; blood disorders, fluid retention, hypertension.
Drug Interactions
Enhances effects of oral anticoagulants (warfarin), phenytoin and sulfonylureas. Increased plasma concentration of lithium, methotrexate and cardiac glycosides. Increased risk of nephrotoxicity when used with ACE inhibitors, cyclosporin, tacrolimus or diuretics; hypokalaemia may also result from ACE inhibitors and diuretics concomitant use. Quinolones may produce convulsions. Moclobemide enhances NSAIDs effects. Increased risk of adverse reactions with other NSAIDs. Increased risk of GI bleeding and ulceration with corticosteroids, SSRIs, clopidrogel and ticlopidine, biphosphonates or pentoxifylline; haemotoxicity with zidovudine. Ritonavir increases plasma concentration; mifepristone and antihypertensives alter the drug's efficacy.
ATC Classification
M01AX04 - azapropazone ; Belongs to the class of other non-steroidal antiinflammatory and antirheumatic products.
Disclaimer: This information is independently developed by CIMS based on azapropazone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in